BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |
ORACLE INVESTMENT MANAGEMENT INC | 555,522 | $3,933,096 | 1.21% |
BRAIDWELL LP | 5,362,980 | $37,969,898 | 1.20% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,275,638 | $16,111,517 | 1.02% |
Sarissa Capital Management LP | 775,000 | $5,487,000 | 0.74% |
Baker Brothers Advisors | 12,710,818 | $89,992,591 | 0.52% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,286,000 | $23,264,880 | 0.51% |
Rock Springs Capital Management LP | 2,551,226 | $18,062,680 | 0.48% |
Eventide Asset Management | 1,970,000 | $13,947,600 | 0.25% |
PDT Partners, LLC | 270,709 | $1,916,620 | 0.24% |
Bison Wealth, LLC | 151,015 | $1,069,186 | 0.21% |
External links
This page lists BIOCRYST PHARMACEUTICALS INC's shareholders in Q3 2023. To view BIOCRYST PHARMACEUTICALS INC's shareholder history, click here.